Lyme Disease Intravenous Treatment
Customize your policy alerts
Sign up for EmblemHealth Policy MG.MM.ME.57d alerts
Get alerted when Policy MG.MM.ME.57d changes without checking for updates manually.
Monitor payer policy activity
Defines medical necessity criteria, acceptable agents, exclusions, and coding for IV antibiotic therapy for members with confirmed Lyme disease; applies to providers requesting preauthorization from EmblemHealth.
Doxycycline added as medically necessary for members intolerant to b-lactam antibiotics.
Repeat or prolonged courses of IV antibiotics not considered medically necessary changed from >4 weeks to >8 weeks.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.